• Roche has launched a new global Phase 3 trial of Elevidys, Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy, enrolling about 100 early ambulatory patients over a 72‑week period to generate additional data for a revised European approval bid.
• This renewed clinical push underscores Roche’s continued commitment to Elevidys and highlights the potential for broader geographic access beyond the United States despite earlier European regulatory setbacks.
• We’ll now examine how Roche’s renewed Phase 3 effort for Elevidys could influence Sarepta’s investment narrative and longer-term growth drivers.

Find 58 companies with promising cash flow potential yet trading below their fair value.

Sarepta Therapeutics Investment Narrative Recap

To own Sarepta, you have to believe ELEVIDYS can grow into a durable global DMD franchise and that the broader genetic medicine pipeline can ultimately support profitability. Roche’s new Phase 3 trial for ELEVIDYS in Europe reinforces the potential for ex-US expansion, but it does not immediately change the near term focus on U.S. uptake and safety management, which remains the biggest current risk.

The ELEVIDYS launch in Japan with Chugai in February ties directly into this new European trial, together pointing to a widening international footprint as a key catalyst. At the same time, ongoing safety work in ENDEAVOR Cohort 8 and the boxed warning for liver injury keep safety, site capacity, and infusion logistics front and center as investors watch how quickly real world adoption can build.

Yet beneath the promise of broader access, investors should be aware of the heightened regulatory and safety risks that could...

Sarepta Therapeutics' narrative projects $1.4 billion revenue and $87.3 million earnings by 2029. This assumes revenue will decrease by 13.3% per year and requires an $800.7 million earnings increase from -$713.4 million today.

Uncover how Sarepta Therapeutics' forecasts yield a $21.65 fair value, in line with its current price.

Exploring Other Perspectives

Some of the lowest analysts were already cautious, assuming about US$2.9 billion of revenue and US$616.4 million of earnings by 2028, and this new Roche trial could either ease their concerns about regulatory drag and capacity bottlenecks or reinforce them, which is why it is worth comparing these more pessimistic views with your own expectations.

Explore 7 other fair value estimates on Sarepta Therapeutics - why the stock might be worth over 5x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Sarepta Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Sarepta Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Sarepta Therapeutics' overall financial health at a glance.

No Opportunity In Sarepta Therapeutics?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.